MX2020008533A - Terapia con oligonucleotidos para la enfermedad de wilson. - Google Patents

Terapia con oligonucleotidos para la enfermedad de wilson.

Info

Publication number
MX2020008533A
MX2020008533A MX2020008533A MX2020008533A MX2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A
Authority
MX
Mexico
Prior art keywords
exon
atp7b
flanking
wilson disease
flanking intron
Prior art date
Application number
MX2020008533A
Other languages
English (en)
Inventor
Frank Schmitges
Daniele Merico
Erno Wienholds
Matthew O''HARA
Original Assignee
Deep Genomics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deep Genomics Incorporated filed Critical Deep Genomics Incorporated
Publication of MX2020008533A publication Critical patent/MX2020008533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03004—Cu2+-exporting ATPase (3.6.3.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a oligonucleótidos antisentido, composiciones y métodos que se dirigen al exón 6 de ATP7B o un intrón flanqueante, modulando así el empalme de pre-ARNm de ATP7B para aumentar el nivel de moléculas de ARNm de ATP7B que tienen exón 6, por ejemplo, para proporcionar una terapia para la enfermedad de Wilson. La presente descripción proporciona un oligonucleótido antisentido que incluye una secuencia de nucleobase al menos 70% complementaria a una secuencia objetivo de ATP7B en el exón 6, un intrón flanqueante en 5', un intrón flanqueante en 3' o una combinación del exón 6 y el intrón flanqueante en 5' o flanqueante en 3'.
MX2020008533A 2018-02-14 2019-02-14 Terapia con oligonucleotidos para la enfermedad de wilson. MX2020008533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630565P 2018-02-14 2018-02-14
PCT/US2019/018076 WO2019161105A1 (en) 2018-02-14 2019-02-14 Oligonucleotide therapy for wilson disease

Publications (1)

Publication Number Publication Date
MX2020008533A true MX2020008533A (es) 2020-11-06

Family

ID=67619598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008533A MX2020008533A (es) 2018-02-14 2019-02-14 Terapia con oligonucleotidos para la enfermedad de wilson.

Country Status (14)

Country Link
US (1) US11578327B2 (es)
EP (1) EP3752614A4 (es)
JP (1) JP2021513851A (es)
KR (1) KR20200120675A (es)
CN (1) CN112041439A (es)
AU (1) AU2019222767A1 (es)
BR (1) BR112020016524A2 (es)
CA (1) CA3090517A1 (es)
CL (1) CL2020002100A1 (es)
CO (1) CO2020010226A2 (es)
IL (1) IL276701A (es)
MX (1) MX2020008533A (es)
SG (1) SG11202007644PA (es)
WO (1) WO2019161105A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117925624B (zh) * 2024-03-22 2024-05-31 上海凌医生物科技有限公司 一种金属响应调控元件

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5578493A (en) * 1993-09-01 1996-11-26 The Trustees Of Columbia University In The City Of New York Wilson's disease gene
CA2108927C (en) 1993-09-21 2008-09-02 Peter Bull Wilson disease gene
CN1120707C (zh) 1995-11-22 2003-09-10 约翰斯·霍普金斯大学 增强生物分子的细胞摄取的配体
US20040101854A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of BCL2-associated athanogene expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030180953A1 (en) 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20040126761A1 (en) * 2002-12-10 2004-07-01 Isis Pharmaceuticals Inc. Modulation of alpha-methylacyl-CoA racemase expression
AU2003273778A1 (en) 2002-10-21 2004-05-04 Exiqon A/S Oligonucleotide analogues for detecting and analyzing nucleic acids
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20070280927A1 (en) * 2004-01-29 2007-12-06 Cellzome Ag Treatment Of Neurodegenerative Diseases By The Use Of Atp7a
AU2005248147A1 (en) 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
EP1784501B1 (en) 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
EP1783645A1 (en) * 2005-11-08 2007-05-09 Actigenics Methods for the identification of microRNA and their applications in research and human health
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4841279B2 (ja) 2006-03-23 2011-12-21 一般財団法人 化学物質評価研究機構 被検物質の発がん性予測方法
CA2708153C (en) 2007-12-04 2017-09-26 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
EP2802658A2 (en) * 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
WO2014036301A1 (en) * 2012-08-30 2014-03-06 Isis Pharmaceuticals, Inc. Modulation of copper related diseases by ctr1
EP2991661B1 (en) 2013-05-01 2019-03-13 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2015002978A2 (en) * 2013-07-02 2015-01-08 The Trustees Of The University Of Pennsylvania Methods for rapid ribonucleic acid fluorescence in situ hybridization
US20160257961A1 (en) 2013-11-06 2016-09-08 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
WO2016004043A1 (en) 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US10822369B2 (en) 2014-11-14 2020-11-03 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
CN105986015B (zh) * 2015-02-05 2020-10-23 大连晶泰生物技术有限公司 一种基于高通量测序的多样本的一个或多个靶序列的检测方法和试剂盒
WO2016170348A2 (en) 2015-04-22 2016-10-27 Mina Therapeutics Limited Sarna compositions and methods of use
WO2017100461A1 (en) 2015-12-08 2017-06-15 Solstice Biologics, Ltd. Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CA3005090A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
KR101743211B1 (ko) 2016-06-24 2017-06-15 주식회사 녹십자지놈 선천성 기능장애 진단용 조성물 및 이의 용도
EP3840758A1 (en) * 2018-08-21 2021-06-30 Deep Genomics Incorporated Therapeutic splice-switching oligonucleotides
CA3218805A1 (en) * 2021-05-10 2022-11-17 Ziqing QIAN Compositions and methods for intracellular therapeutics
WO2022256283A2 (en) * 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar

Also Published As

Publication number Publication date
AU2019222767A1 (en) 2020-08-27
US11578327B2 (en) 2023-02-14
JP2021513851A (ja) 2021-06-03
CO2020010226A2 (es) 2020-12-10
CN112041439A (zh) 2020-12-04
WO2019161105A1 (en) 2019-08-22
IL276701A (en) 2020-09-30
EP3752614A4 (en) 2021-11-10
BR112020016524A2 (pt) 2021-09-28
KR20200120675A (ko) 2020-10-21
CL2020002100A1 (es) 2021-01-29
CA3090517A1 (en) 2019-08-22
EP3752614A1 (en) 2020-12-23
US20210032629A1 (en) 2021-02-04
SG11202007644PA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
NZ733882A (en) Compositions for modulating c9orf72 expression
MX2022013356A (es) Avv que codifica mirna dirigido al gen htt y usos del mismo.
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
MX2020001912A (es) Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
MX2010009195A (es) Rnas ultrapequeños como antagonistas del receptor tipo toll-3.
EA201791820A1 (ru) Олигонуклеотидная терапия врожденного амавроза лебера
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
SG10201808903UA (en) Compositions for modulating c9orf72 expression
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
MX2021012126A (es) Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
MX2016012123A (es) Composiciones para modular la expresion de ataxina 2.
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
WO2008073923A3 (en) Mirna regulated genes and pathways as targets for therapeutic intervention
EA201892366A1 (ru) Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
CL2021001488A1 (es) Transposasa de piggybac mutada
MX2020007433A (es) Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
MX2020008533A (es) Terapia con oligonucleotidos para la enfermedad de wilson.
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
CY1123599T1 (el) Συνθεσεις και μεθοδοι για τη διορθωση ζωνιαιας μυικης δυστροφιας τυπου 2c με τη χρησιμοποιηση παραλειψης εξονιων
MX2021000998A (es) Oligonucleotidos antisentido de acetil-coa carboxilasa2.